Tanja Cufer discusses the abstracts presented in lung cancer track at ASCO 2016 Annual Congress. Due to treatment advances and longer lifespan in NSCLC patients with oncogene-driven disease, brain and leptomeningeal metastases are nowadays often. She discusses the efficacy results from several newer agents in that setting. In addition, she discusses the results with a new Antibody-drug conjugate in metastatic setting, as well as milestone analyses with immune checkpoint inhibitors, targeted therapy and standard therapy in trials submitted to the US FDA.

Oncology Meeting Resources

Major Sponsors

Janssen Servier

Main Sponsors

Amgen Astellas AstraZeneca Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo Genomic Health Inc. Lilly Oncology Nutricia Roche